Better Context → Better Decisions
Context counts in life sciences. The FENIX analyst team is tirelessly using its experience to put you in a position to succeed. Below, our readers with corporate access will find a wealth of contextualized life science insight ready to be viewed in the FENIX Marketplace.
Welcome to FENIX Syndicated Services. If you already have an account, please log in. If you have any questions or would like to subscribe to our services, please contact us.
$599
Posted in: Dual/triple agonist, GLP-1RA, Other, Topics Mar 06 | 2025Amgen Initiates Ph3 MariTide Trials; LifeMD and Teladoc Integrate with LillyDirect; Arrowhead Preclinical Obesity DataPurchase Blast
$599
Posted in: GLP-1RA, Other, Topics Mar 06 | 2025Novo Launches NovoCare DTP Platform; Lilly Manufacturing Pitches from States and Initiates TRIUMPH-6Purchase Blast
$599
Posted in: GLP-1RA, Glucose Monitoring, Insulin Delivery, Other, Topics Mar 04 | 2025New Lilly TV Ad; Novo Updates Ozempic Promo Campaign; Senseonics, Fractyl, and Esperion Q4 ‘24 Earnings UpdatesPurchase Blast
$599
Posted in: GLP-1RA, Other, Topics Mar 04 | 2025AbbVie Enters Obesity Race; Novo Initiates New Drug Development AI Partnership; Biocon Launches Generic Liraglutide in UKPurchase Blast
$599
Posted in: Dual/triple agonist, GLP-1RA, Glucose Monitoring, Insulin Delivery, Other, Topics Feb 28 | 2025Tandem, Altimmune, MannKind, Silence, and Viatris Q4 ’24 Earnings; Zevra Sells PRV; TIXiMED Ph1 TIX100 Trial UpdatePurchase Blast
$599
Posted in: GLP-1RA, Glucose Monitoring, Other, Topics Feb 27 | 2025Madrigal and NewAmsterdam Q4 ’24 Earnings; Lilly Manufacturing Expansion and Acquisition Update; New Eversense 365 Platform Integration Purchase Blast
$599
Posted in: GLP-1RA, Glucose Monitoring, Other, Topics Feb 25 | 2025Lilly Doubles Down on LillyDirect Program; Tandem AID Algorithm Cleared for T2DM; Compounders Sue FDA… Again; Lilly Acquires FXR Program; Terns Development UpdatesPurchase Blast
$599
Posted in: Basal Insulin, GLP-1RA, GLP-1RA + Basal, Other, SGLT2i, Topics Feb 25 | 2025Lilly Stockpiles Orfoglipron; February CHMP Agenda ObservedPurchase Blast
$599
Posted in: Other, Topics Feb 25 | 2025Coming Soon: FENIX Obesity Spotlight SeriesPurchase Blast
$599
Posted in: GLP-1RA, Glucose Monitoring, Insulin Delivery, Other, Topics Feb 21 | 2025Sema Shortage Resolved; Pfizer/Viking M&A Rumor; Insulet Q4 ’24 EarningsPurchase Blast
$599
Posted in: Dual/triple agonist, GLP-1RA, Glucose Monitoring, Other, Topics Feb 20 | 2025Zealand FY Q4 ‘24 Earnings; Steve Pacelli Leaves DexcomPurchase Blast
$599
Posted in: Glucose Monitoring, Insulin Delivery, Topics Feb 19 | 2025New Tandem AID Algorithm TrialPurchase Blast
$599
Posted in: Basal Insulin, Bolus Insulin, Dual/triple agonist, GLP-1RA, Glucose Monitoring, Insulin Delivery, Other, Topics Feb 18 | 2025Medtronic CY Q4 ’24 (FY Q3 ‘25) Earnings; FDA Approves Biosimilar Novolog; Allurion Balloon + GLP-1RA; Ph2 Oral VK2735 Trial ObservedPurchase Blast
$599
Posted in: Glucose Monitoring, Insulin Delivery, Other, Topics Feb 14 | 2025Dexcom Q4 '24 EarningsPurchase Blast
$599
Posted in: Dual/triple agonist, GLP-1RA, Other, Topics Feb 13 | 2025Zepbound SDV Label Update; Semaglutide Reduces Alcohol Cravings; Alnylam Q4 ’24 Earnings; NYT Article Features HCPs Using GLP-1RAs; Aardvark IPOPurchase Blast
$599
Posted in: Other, Topics Feb 12 | 2025Inventiva Prioritizes Lanifibranor; TIXiMED Initiates Ph1 TIX100 Trial; Diamyd Receives Additional FinancingPurchase Blast
$599
Posted in: Basal Insulin, GLP-1RA, Other, Topics Feb 11 | 2025Novo Warns Against Compounders; Arrowhead (FY Q1 ‘25) and Vertex CY Q4 ‘24 Earnings; Oramed Enters Agreement for Oral InsulinPurchase Blast
$599
Posted in: GLP-1RA, Other, Topics Feb 10 | 2025Lilly and OliX Partner in MASH; Hims & Hers Super Bowl Ad Controversy; Novartis Initiates Pelacarsen/Inclisiran Trial in Lp(a)Purchase Blast
$599
Posted in: GLP-1RA, Other, Topics Feb 07 | 2025Ozempic CKD Label and Website AnalysisPurchase Blast
$599
Posted in: Dual/triple agonist, GLP-1RA, Other, Topics Feb 06 | 2025Orforglipron Takes Center Stage; Lilly Q4 ’24 Earnings CallPurchase Blast